177lu-dtpa-omburtamab
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2020 (NCT04167618)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CD276 antigenINHIBITOR
CD276 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 177-Lutetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04315246 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2020 | Y-Mabs, Inc |
| NCT04167618 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2020 | Y-Mabs, Inc |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Y-Mabs, Inc | For profit | 2 | 2 | 1 | 2020 |
1 organizations
Page 1 / 1